203 related articles for article (PubMed ID: 22398067)
1. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients.
Helwig U; Müller M; Hedderich J; Schreiber S
J Crohns Colitis; 2012 May; 6(4):419-24. PubMed ID: 22398067
[TBL] [Abstract][Full Text] [Related]
2. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
3. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
[TBL] [Abstract][Full Text] [Related]
5. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy.
Greveson K; Goodhand J; Capocci S; Woodward S; Murray C; Cropley I; Hamilton M; Lipman M
J Crohns Colitis; 2013 Jun; 7(5):412-8. PubMed ID: 23009739
[TBL] [Abstract][Full Text] [Related]
6. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
[TBL] [Abstract][Full Text] [Related]
7. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.
Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Angelberger S; Novacek G; Mikulits A; Vogelsang H; Reinisch W
Eur J Clin Invest; 2011 Oct; 41(10):1071-6. PubMed ID: 21413978
[TBL] [Abstract][Full Text] [Related]
8. Low Indeterminate Rates Associated With Use of the QuantiFERON-TB Gold In-Tube Test in Children With Inflammatory Bowel Disease on Long-term Infliximab.
Vortia E; Uko VE; Yen-Lieberman B; Frawley J; Worley SE; Danziger-Isakov L; Kaplan B; Mahajan L
Inflamm Bowel Dis; 2018 Mar; 24(4):877-882. PubMed ID: 29562270
[TBL] [Abstract][Full Text] [Related]
9. Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease.
Hradsky O; Ohem J; Zarubova K; Mitrova K; Durilova M; Kotalova R; Nevoral J; Zemanova I; Dryak P; Bronsky J
J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):320-4. PubMed ID: 24126833
[TBL] [Abstract][Full Text] [Related]
10. Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?
Cabriada JL; Ruiz-Zorrilla R; Barrio J; Atienza R; Huerta A; Rodríguez-Lago I; Bernal A; Herrero C
Turk J Gastroenterol; 2018 May; 29(3):292-298. PubMed ID: 29755013
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
[TBL] [Abstract][Full Text] [Related]
12. Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients.
Wong SH; Ip M; Tang W; Lin Z; Kee C; Hung E; Lui G; Lee N; Chan FK; Wu JC; Sung JJ; Ng SC
Inflamm Bowel Dis; 2014 Nov; 20(11):2067-72. PubMed ID: 25159454
[TBL] [Abstract][Full Text] [Related]
13. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
14. The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients.
Abreu C; Almeida F; Ferraz R; Dias CC; Sarmento A; Magro F
Dig Liver Dis; 2016 Dec; 48(12):1438-1443. PubMed ID: 27599804
[TBL] [Abstract][Full Text] [Related]
15. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.
Vajravelu RK; Osterman MT; Aberra FN; Roy JA; Lichtenstein GR; Mamtani R; Goldberg DS; Lewis JD; Scott FI
Inflamm Bowel Dis; 2017 Dec; 24(1):217-226. PubMed ID: 29272482
[TBL] [Abstract][Full Text] [Related]
16. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients.
Yilmaz N; Zehra Aydin S; Inanc N; Karakurt S; Direskeneli H; Yavuz S
Lupus; 2012 Apr; 21(5):491-5. PubMed ID: 22140142
[TBL] [Abstract][Full Text] [Related]
17. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
[TBL] [Abstract][Full Text] [Related]
18. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
[TBL] [Abstract][Full Text] [Related]
19. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents.
Kim KH; Lee SW; Chung WT; Kim BG; Woo KS; Han JY; Kim JM
Korean J Lab Med; 2011 Oct; 31(4):271-8. PubMed ID: 22016681
[TBL] [Abstract][Full Text] [Related]
20. Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country.
Bourgarit A; Baron G; Breton G; Tattevin P; Katlama C; Allavena C; Campa P; Ravaud P; Lortholary O; Carcelain G;
Ann Am Thorac Soc; 2015 Aug; 12(8):1138-45. PubMed ID: 26213798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
